Upon completion of this activity, participants should be able to:

• Describe how pharmacogenomic variation affects the toxicity and efficacy of antidepressants in the context of depressive disorders.
• Analyze and interpret pharmacogenomic (PGx) test results utilizing CPIC guidelines for SSRIs.
• Discuss clinical decision-making in PGx including phenoconversion and drug-drug interactions.
• Explore best practices for returning pharmacogenomic (PGx) test results to patients and documentation of PGx test results.

Disclaimer Statement:

The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.